Remove Degenerative Disc Disease Remove Events Remove Lower Back Pain
article thumbnail

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

OrthoSpineNews

No serious adverse events (SAEs) were reported, and there was no dose (40X10 6 cells) limiting toxicity at 26-104 weeks. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.

article thumbnail

The 18 Most Popular Chiropractic Tools and Equipment

ChiroTouch

Lightweight and easily transportable, portable tables are ideal for chiropractors who offer mobile services or need a flexible option for outreach events and home visits. These tables can be adjusted vertically, allowing the chiropractor to raise or lower them to the optimal working height. Portable tables. Elevation tables.

X-ray 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Enhancing Well-Being Through Chiropractic Spinal Adjustments

Any Spine

Alleviating Chronic Back and Neck Pain Chiropractic spinal adjustments have proven effective in alleviating chronic back and neck pain, particularly for individuals with conditions such as degenerative disc disease.

article thumbnail

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

OrthoSpineNews

Compelling Clinical Signals: Over 74% of subjects showed >50% improvement in function (ODI) by 52 weeks; Over 72% of subjects reported >50% reduction in pain (VAS) by 52 weeks; Combined >50% improvement in both ODI and VAS measures was achieved by a meaningful portion of subjects across all timepoints. We have also obtained U.S.

article thumbnail

BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

OrthoSpineNews

Disc/Spine Program In a February podium presentation at the Orthopaedic Research Society (ORS) Annual Meeting, BioRestoratives Vice President of Research and Development, Francisco Silva, presented 2652 week blinded data from the first 15 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100.